Pancreatic Cancer Research

ResearcherSun Yat-sen UniversityActive in the last 2 years

Dongxin Lin

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0002-8723-8868; OpenAlex author ID A5100674237. Sources: OpenAlex.

Their work

Papers
23 (first author 0, last author 6)
Trials
0
Grants
0
Labs led
1
Collaborators
68
Papers, trials and grants by year

2011: 1 paper · 2012: 1 paper · 2013: 1 paper · 2014: 1 paper · 2015: none · 2016: 1 paper · 2017: none · 2018: 2 papers · 2019: 1 paper · 2020: none · 2021: 5 papers · 2022: none · 2023: 4 papers · 2024: 1 paper · 2025: 5 papers

Papers 23

  1. Extracellular vesicles from obese visceral adipose promote pancreatic cancer development and resistance to immune checkpoint blockade therapy. Co-author DOI 10.1016/j.cmet.2025.10.015↗
  2. CSTF2-impeded innate αβ T cell infiltration and activation exacerbate immune evasion of pancreatic cancer. Co-author DOI 10.1038/s41418-025-01464-0↗
  3. Author Correction: Exome-wide analysis identifies three low-frequency missense variants associated with pancreatic cancer risk in Chinese populations. Co-author DOI 10.1038/s41467-025-58613-9↗
  4. Psychological stress-induced ALKBH5 deficiency promotes tumour innervation and pancreatic cancer via extracellular vesicle transfer of RNA. Co-author DOI 10.1038/s41556-025-01667-0↗
  5. Targeting MXD1 sensitises pancreatic cancer to trametinib. Co-author DOI 10.1136/gutjnl-2024-333408↗
  6. KHSRP Stabilizes m6A-Modified Transcripts to Activate FAK Signaling and Promote Pancreatic Ductal Adenocarcinoma Progression. Co-author DOI 10.1158/0008-5472.can-24-0927↗
  7. LncRNA BCAN-AS1 stabilizes c-Myc via N6-methyladenosine-mediated binding with SNIP1 to promote pancreatic cancer. Co-author DOI 10.1038/s41418-023-01225-x↗
  8. CSTF2 mediated mRNA N6-methyladenosine modification drives pancreatic ductal adenocarcinoma m6A subtypes. Co-author DOI 10.1038/s41467-023-41861-y↗
  9. Super-enhancer RNA m6A promotes local chromatin accessibility and oncogene transcription in pancreatic ductal adenocarcinoma. Co-author DOI 10.1038/s41588-023-01568-8↗
  10. N 6-methyladenosine Modification of FZR1 mRNA Promotes Gemcitabine Resistance in Pancreatic Cancer. Co-author DOI 10.1158/0008-5472.can-22-3346↗
  11. Metformin inhibits pancreatic cancer metastasis caused by SMAD4 deficiency and consequent HNF4G upregulation. Co-author DOI 10.1007/s13238-020-00760-4↗
  12. LINC00842 inactivates transcription co-regulator PGC-1α to promote pancreatic cancer malignancy through metabolic remodelling. Co-author DOI 10.1038/s41467-021-23904-4↗
  13. N6 -methyladenosine-Mediated Upregulation of WTAPP1 Promotes WTAP Translation and Wnt Signaling to Facilitate Pancreatic Cancer Progression. Co-author DOI 10.1158/0008-5472.can-21-0494↗
  14. Inflammatory cytokine-regulated tRNA-derived fragment tRF-21 suppresses pancreatic ductal adenocarcinoma progression. Co-author DOI 10.1172/jci148130↗
  15. Genome-wide identification and characterization of circular RNA m6A modification in pancreatic cancer. Co-author DOI 10.1186/s13073-021-01002-w↗
  16. Excessive miR-25-3p maturation via N6-methyladenosine stimulated by cigarette smoke promotes pancreatic cancer progression. Last author DOI 10.1038/s41467-019-09712-x↗
  17. Exome-wide analysis identifies three low-frequency missense variants associated with pancreatic cancer risk in Chinese populations. Co-author DOI 10.1038/s41467-018-06136-x↗
  18. Functional role of BTB and CNC Homology 1 gene in pancreatic cancer and its association with survival in patients treated with gemcitabine. Last author DOI 10.7150/thno.23978↗
  19. Pancreatic cancer risk variant in LINC00673 creates a miR-1231 binding site and interferes with PTPN11 degradation. Last author DOI 10.1038/ng.3568↗
  20. Genome-wide association study of survival in patients with pancreatic adenocarcinoma. Co-author DOI 10.1136/gutjnl-2012-303477↗
  21. Identification of common variants in BRCA2 and MAP2K4 for susceptibility to sporadic pancreatic cancer. Last author DOI 10.1093/carcin/bgt004↗
  22. Copy number variation at 6q13 functions as a long-range regulator and is associated with pancreatic cancer risk. Last author DOI 10.1093/carcin/bgr228↗
  23. Genome-wide association study identifies five loci associated with susceptibility to pancreatic cancer in Chinese populations. Last author DOI 10.1038/ng.1020↗

Closest collaborators

The 25 strongest of 68 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Jian Zheng · 16 shared papers, 2016–2025 · strength 2.05
  2. Xudong Huang · 15 shared papers, 2016–2025 · strength 1.99
  3. Jialiang Zhang · 14 shared papers, 2019–2025 · strength 1.94
  4. Lingxing Zeng · 12 shared papers, 2021–2025 · strength 1.77
  5. Shaoping Zhang · 11 shared papers, 2021–2025 · strength 1.58
  6. Ziming Chen · 6 shared papers, 2023–2025 · strength 1.05
  7. Zilan Xu · 6 shared papers, 2023–2025 · strength 1.05
  8. Chunling Xue · 6 shared papers, 2023–2025 · strength 1.05
  9. Rufu Chen · 9 shared papers, 2019–2024 · strength 1.05
  10. Jiachun Su · 9 shared papers, 2019–2023 · strength 1.02
  11. Quanbo Zhou · 6 shared papers, 2023–2025 · strength 0.91
  12. Xiaowei He · 5 shared papers, 2023–2025 · strength 0.86
  13. Chen Hsuan Wu · 11 shared papers, 2011–2025 · strength 0.81
  14. Yanfen Zheng · 7 shared papers, 2019–2023 · strength 0.75
  15. Rui Li · 5 shared papers, 2021–2024 · strength 0.68
  16. Ying Ye · 6 shared papers, 2019–2023 · strength 0.64
  17. Zhixiang Zuo · 5 shared papers, 2019–2023 · strength 0.55
  18. Junge Deng · 5 shared papers, 2021–2023 · strength 0.54
  19. Guandi Wu · 4 shared papers, 2021–2023 · strength 0.44
  20. Xu Che · 7 shared papers, 2011–2021 · strength 0.41
  21. Lusheng Wei · 4 shared papers, 2021 · strength 0.40
  22. Xiaoyu Wu · 2 shared papers, 2025 · strength 0.38
  23. Ling Pan · 4 shared papers, 2019–2021 · strength 0.36
  24. Xiaoping Miao · 5 shared papers, 2011–2025 · strength 0.32
  25. Jiang Chang · 4 shared papers, 2011–2025 · strength 0.30

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.